Search

Your search keyword '"Yu. V. Omarova"' showing total 6 results
Start Over Author "Yu. V. Omarova"
6 results on '"Yu. V. Omarova"'

1. Clinical features of post-COVID period. Results of an International Register 'Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)' (12-month follow-up)

Author

G. P. Arutyunov, E. I Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigorieva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateishchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanav, S. A. Sayganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Sh'ukarev, A. K. Abdrakhmanova, S. A. Avetisian, H. G. Avoyan, K. K. Azarian, G. T. Aimakhanova, D. A. Ayipova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, T. I. Batluk, A. S. Batchayeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteyev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Gаlova, V. V Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigorieva, E. U. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duyshobayev, D. S. Evdokimov, K. E. Egorova, A. E. Zheldybayeva, N. V. Zarechnova, Yu. D. Zimina, S. U. Ivanova, E. U. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Кaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Koliadich, O. V. Kondriakova, M. P. Konoval, D. U. Konstantinov, E. A. Konstantinova, V. A. Kordukova, E. V. Koroleva, A. U. Kraposhina, T. V. Kryukova, A. S. Kuznetsova, T. U. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. U. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeyeva, K. V. Mazalov, V. I. Maiseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelian, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. U. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pahomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofeva, J. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, I. V. Samus, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortcova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagayeva, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostianetckaia, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. U. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. U. Shishkov, S. U. Sherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
covid-19, post-covid period, readmissions, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To investigate on post-COVID period in patients of the Eurasian region.Material and methods. A total of 9364 consecutively hospitalized patients were included in ACTIV registry. Enrollment of patients began on June 29, 2020, and was completed on March 30, 2021, corresponding to the first and second waves of the pandemic. Demographic, clinical, and laboratory data, computed tomography (CT) results, information about inhospital clinical course and complications of COVID-19 during hospitalization were extracted from electronic health records using a standardized data collection form. The design included follow-up telephone interviews with a standard questionnaire at 3, 6, and 12 months to examine the course of post-COVID period.Results. According to ACTIV register, 63% of patients after COVID-19 had new adverse symptoms or exacerbations of the existing symptoms lasting for up to 1 year. After hospital discharge, 79,8% of patients sought unscheduled medical attention in the first 3 months, 79,1% at 4-6 months, and 64,8% at 7-12 months. Readmission rate was 11,8% in the first 3 months, 10,9% at 4-6 months, and 10,1% at 7-12 months. The most common reasons for unscheduled treatment in the first 3 months were uncontrolled hypertension, decompensated type 2 diabetes, destabilization of coronary artery disease, gastrointestinal disease, AF episodes, exacerbation of asthma and chronic obstructive pulmonary disease, decompensated heart failure (HF). The 12-month mortality of COVID-19 survivors after the discharge was 3,08%. Multivariate analysis showed that independent risk factors for fatal outcome were age (direct correlation), the levels of hemoglobin (inverse correlation), oxygen saturation (inverse correlation), and aspartate aminotransferase (direct correlation), as well as class III-IV HF, prior stroke, cancer, inhospital acute kidney injury. Based on these identified risk factors, a nomogram was constructed to determine the 3-month mortality risk after discharge.Conclusion. Analysis of ACTIV register showed that end of the acute phase of COVID-19 does not imply a complete recovery.

Published
2023
Full Text
View/download PDF

2. Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry 'Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors'

Author

G. P. Arutyunov, E. I. Tarlovskaya, A. G. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, G. G. Airapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigorieva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateyshchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanov, S. A. Saiganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Schukarev, A. K. Abdrakhmanova, S. A. Avetisyan, O. G. Avoyan, K. K. Azaryan, G. T. Aimakhanova, D. A. Aiypova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, T. I. Batluk, A. S. Batchaeva, R. A. Bashkinov, A. M. Bitieva, I. U. Bikhteev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Galova, V. V. Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigoryeva, E. Yu. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duishobaev, D. S. Evdokimov, K. E. Egorova, A. N. Ermilova, A. E. Zheldybaeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilyina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Kaskaeva, K. F. Kasymova, J. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, A. V. Klimova, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondryakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordyukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kryukova, A. P. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeeva, K. V. Mazalov, V. I. Mayseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelyan, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. Yu. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pakhomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofieva, Yu. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortsova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagaeva, Yu. V. Titoikina, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostyanetskaya, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. Yu Shishkov, S. Yu. Shcherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
covid-19, low density lipoproteins, cholesterol, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To study the lipid profile in hospitalized patients with coronavirus disease 2019 (COVID-19) depending on the outcome of its acute phase according to the AKTIV international registry.Material and methods. The AKTIV registry included men and women over 18 years of age with a diagnosis of COVID-19, who were treated in a hospital. A total of 9364 patients were included in the registry, of which 623 patients were analyzed for levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglycerides on days 1-2 of hospitalization. The level of high-density lipoprotein cholesterol (HDL-C) was calculated using the Friedewald equation.Results. We found that a decrease in LDL-C level was significantly associated with an unfavorable prognosis for hospitalized patients with COVID-19. This pattern persisted in both univariate and multivariate analyses. LDL-C levels in the final multivariate model had a significant relationship with the prognosis (an increase in the death risk by 1,7 times with a decrease per 1 mmol/l). In addition, we found that the survival of patients with an indicator level of

Published
2022
Full Text
View/download PDF

3. Contribution of the COVID-19 pandemic to the prognosis of patients with class III-IV heart failure

Author

A. R. Vaisberg, I. V. Fomin, D. S. Polyakov, and Yu. V. Omarova

Subjects
heart failure, prognosis, mortality dynamics, covid-19, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To study the survival of patients with New York Heart Association (NYHA) class IIIV heart failure (HF) after a coronavirus disease 2019 (COVID-19) and compare it with a group of similar patients without COVID-19, both during and before the pandemic.Material and methods. A sample of 810 patients with HF of any class was created, who were treated in the HF center at the City Clinical Hospital № 38 in Nizhny Novgorod for the period from March 2019 to March 2020. Patients with NYHA class HF III-IV (n=263) were selected from this sample. The diagnosis was confirmed by echocardiography and chest radiography. At the time of discharge, the 6-minute walk test was 300 pg/ml. The group was analyzed from March 2019 to December 2021 with the definition of all-cause mortality depending on prior COVID-19.Results. During 520-day follow-up, 30,8% of NYHA class III-IV patients died, while 16,0% of patients underwent COVID-19, of which 79,25% of patients died during this period. Mortality among patients without prior COVID-19 was 23,3% (p

Published
2022
Full Text
View/download PDF

4. Carbohydrate metabolism disorders in patients with heart failure: data from the local registry

Author

A. R. Vaisberg, E. I. Tarlovskaya, I. V. Fomin, D. S. Polyakov, and Yu. V. Omarova

Subjects
heart failure, carbohydrate metabolism disorders, diabetes, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Aim. To study the prevalence of carbohydrate metabolism disorders in patients with heart failure (HF) hospitalized in the city HF center.Material and methods. According to the local registry, the study sequentially included 183 patients (99 men and 84 women) hospitalized in the Nizhny Novgorod city HF center from September 1, 2019. The examination and treatment were carried out in accordance with the current clinical guidelines. In the first 48 hours after hospitalization, the concentration of the N-terminal pro-brain natriuretic peptide, soluble stimulating growth factor 2 (sST2), neutrophil gelatinase-associated lipocalin, cystatin C, blood creatinine was determined. The glomerular filtration rate was calculated using the СKDEPI equation. To assess the carbohydrate metabolism disorders, all patients were studied for fasting plasma glucose, glycated hemoglobin (HbA1c) and fructosamine. Statistical data processing was carried out using the R statistics package (R Core Team (2019)).Results. The incidence of carbohydrate metabolism disorders among patients withdecompensated HF was 75,89%, including previously diagnosed type 2 diabetes in 31,25%, newly diagnosed dysglycemia in 44,64% of patients. Less than one fourth of patients had normal parameters of carbohydrate metabolism according to HbA1c, fructosamine and fasting plasma glucose. The severity of carbohydrate metabolism disorders was significantly correlated with the severity of HF according to the following criteria: 6-minute walk test, HF functional class, sST2 level, and some parameters of cardiac remodeling. Among the criteria used for carbohydrate metabolism disorders, the HbA1c level was most closely associated with the criteria for HF severity.Conclusion. Carbohydrate metabolism disorders in HF patients are widespread and underdiagnosed during routine examination. The interrelation of carbohydrate metabolism parameters and indicators of HF severity is rationale for active detection of dysglycemia in these patients in order to potentially influence the prognosis.

Published
2021
Full Text
View/download PDF

5. The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries

Author

A. G. Arutyunov, E. I. Tarlovskaya, G. R. Galstyan, T. I. Batluk, R. A. Bashkinov, G. P. Arutyunov, Yu. N. Belenkov, A. O. Konradi, Yu. M. Lopatin, A. P. Rebrov, S. N. Tereshchenko, A. I. Chesnikova, H. G. Hayrapetyan, A. P. Babin, I. G. Bakulin, N. V. Bakulina, L. A. Balykova, A. S. Blagonravova, M. V. Boldina, M. I. Butomo, A. R. Vaisberg, A. S. Galyavich, V. V. Gomonova, N. Yu. Grigoryeva, I. V. Gubareva, I. V. Demko, A. V. Evzerikhina, A. V. Zharkov, A. A. Zateishchikova, U. K. Kamilova, Z. F. Kim, T. Yu. Kuznetsova, A. N. Kulikov, N. V. Lareva, E. V. Makarova, S. V. Malchikova, S. V. Nedogoda, M. M. Petrova, I. G. Pochinka, K. V. Protasov, D. N. Protsenko, D. Yu. Ruzanov, S. A. Saiganov, A. Sh. Sarybaev, N. M. Selezneva, A. B. Sugraliev, I. V. Fomin, O. V. Khlynova, O. Yu. Chizhova, I. I. Shaposhnik, D. A. Schukarev, A. K. Abdrakhmanova, S. A. Avetisyan, H. G. Avoyan, K. K. Azaryan, G. T. Aimakhanova, D. A. Ayypova, A. Ch. Akunov, M. K. Alieva, A. R. Almukhambedova, A. V. Aparkina, O. R. Aruslanova, E. Yu. Ashina, O. Yu. Badina, O. Yu. Barysheva, A. S. Batchaeva, A. M. Bitieva, I. U. Bikhteev, N. A. Borodulina, M. V. Bragin, V. A. Brazhnik, A. M. Budu, G. A. Bykova, K. R. Vagapova, D. D. Varlamova, N. N. Vezikova, E. A. Verbitskaya, O. E. Vilkova, E. A. Vinnikova, V. V. Vustina, E. A. Galova, V. V. Genkel, D. B. Giller, E. I. Gorshenina, E. V. Grigoryeva, E. Yu. Gubareva, G. M. Dabylova, A. I. Demchenko, O. Yu. Dolgikh, M. Y. Duishobaev, D. S. Evdokimov, K. E. Egorova, A. N. Ermilova, A. E. Zheldybaeva, N. V. Zarechnova, Yu. D. Zimina, S. Yu. Ivanova, E. Yu. Ivanchenko, M. V. Ilina, M. V. Kazakovtseva, E. V. Kazymova, Yu. S. Kalinina, N. A. Kamardina, A. M. Karachenova, I. A. Karetnikov, N. A. Karoli, M. Kh. Karsiev, D. S. Kaskaeva, K. F. Kasymova, Zh. B. Kerimbekova, E. S. Kim, N. V. Kiseleva, D. A. Klimenko, A. V. Klimova, O. V. Kovalishena, S. V. Kozlov, E. V. Kolmakova, T. P. Kolchinskaya, M. I. Kolyadich, O. V. Kondryakova, M. P. Konoval, D. Yu. Konstantinov, E. A. Konstantinova, V. A. Kordyukova, E. V. Koroleva, A. Yu. Kraposhina, T. V. Kryukova, A. S. Kuznetsova, T. Yu. Kuzmina, K. V. Kuzmichev, Ch. K. Kulchoroeva, T. V. Kuprina, I. M. Kuranova, L. V. Kurenkova, N. Yu. Kurchugina, N. A. Kushubakova, V. I. Levankova, A. A. Ledyaeva, T. V. Lisun, V. E. Lisyanskaya, N. A. Lyubavina, N. A. Magdeeva, K. V. Mazalov, V. I. Mayseenko, A. S. Makarova, A. M. Maripov, N. V. Markov, A. A. Marusina, E. S. Melnikov, A. I. Metlinskaya, N. B. Moiseenko, F. N. Muradova, R. G. Muradyan, Sh. N. Musaelyan, E. S. Nekaeva, N. M. Nikitina, S. E. Nifontov, E. Yu. Obolentseva, A. A. Obukhova, B. B. Ogurlieva, A. A. Odegova, Yu. V. Omarova, N. A. Omurzakova, Sh. O. Ospanova, V. A. Pavlova, E. V. Pakhomova, L. D. Petrov, S. S. Plastinina, D. A. Platonov, V. A. Pogrebetskaya, D. V. Polyakov, D. S. Polyakov, E. V. Ponomarenko, L. L. Popova, A. A. Potanin, N. A. Prokofieva, Yu. D. Rabik, N. A. Rakov, A. N. Rakhimov, N. A. Rozanova, I. V. Samus, S. Serikbolkyzy, Ya. A. Sidorkina, A. A. Simonov, V. V. Skachkova, R. D. Skvortsova, D. S. Skuridin, D. V. Solovieva, I. A. Solovieva, I. M. Sukhomlinova, A. G. Sushilova, D. R. Tagaeva, Yu. V. Titoykina, E. P. Tikhonova, D. S. Tokmin, A. A. Tolmacheva, M. S. Torgunakova, K. V. Trenogina, N. A. Trostyanetskaya, D. A. Trofimov, M. A. Trubnikova, A. A. Tulichev, A. T. Tursunova, N. D. Ulanova, O. V. Fatenkov, O. V. Fedorishina, T. S. Fil, I. Yu. Fomina, I. S. Fominova, I. A. Frolova, S. M. Tsvinger, V. V. Tsoma, M. B. Cholponbaeva, T. I. Chudinovskikh, I. V. Shavrin, O. A. Shevchenko, D. R. Shikhaliev, E. A. Shishkina, K. Yu. Shishkov, S. Yu. Shcherbakov, G. V. Shcherbakova, and E. A. Yausheva

Subjects
Endocrinology, Diabetes and Metabolism
Abstract

BACKGROUND. There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).AIM. To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.MATERIALS AND METHODS. AKTIV and AKTIV 2 are multicenter non-interventional real-world registers. The АКТИВ registry (n=6396) includes non-overlapping outpatient and inpatient arms with 6 visits in each. The АКТИВ 2 registry (n=2968) collected the data of hospitalized patients and included 3 visits. All subjects were divided into 3 groups: not overweight (n=2139), overweight (n=2931) and obese (n=2666).RESULTS. A higher BMI was significantly associated with a more severe course of the infection in the form of acute kidney injury (p=0.018), cytokine storm (pCONCLUSION. Overweight and/or obesity is a significant risk factor for severe course of the new coronavirus infection and the associated cardiovascular and kidney damage Overweight people and patients with the 1st and 2nd degree obesity tend to have a high risk of death of SARS-CoV-2 infection in both acute and post-covid periods. On top of that, in case of morbid obesity patients this tendency is statistically significant. Normalization of body weight is a strategic objective of modern medicine and can contribute to prevention of respiratory conditions, severe course and complications of the new coronavirus infection.

Published
2023

6. Analysis of the compliance of the prescribed therapy with the EURO FORTA system in polymorbidic patients of elderly and old age with CHF

Author

E I, Tarlovskaya and Yu V, Omarova

Subjects
Heart Failure, Chronic Disease, Humans, Female, Stroke Volume, Cardiology and Cardiovascular Medicine, Ventricular Function, Left, Aged, Retrospective Studies
Abstract

Aim To study the consistency of the prescribed therapy with the EURO FORTA (2018) system in polymorbid patients with chronic heart failure (CHF) according to data of the local registry.Material and methods The study included 313 patients with CHF aged 75±8.2 years. The Charlson Comorbidity Index (CCI) and the number of diseases (1–2, 3–5, >5) were calculated for all patients. Inpatient and outpatient treatment was assessed according to the EURO FORTA (2018) system based on polymorbidity degree, age, gender, and CHF type and severity.Results For the retrospective analysis of outpatient treatment, 5 groups of patients were isolated based on the drug class in the EURO FORTA system: group 1, patients treated only with class A drugs (3.51 %); group 2, class A and B drugs (22.36 %); group 3, class A, B, and C drugs (17.25 %); group 4, class A, B, C, and D drugs 10.86 % (А, В, С, D) and 16.31 % (А, В, D); and group 5, patients without an outpatient drug therapy (29.71 %). For the analysis of inpatient treatment, 4 groups of patients were isolated based on the drug class in the EURO FORTA system: group 1, patients treated only with class A drugs (0.32 %); group 2, class A and B drugs (15.97 %); group 3, class A, B, and C drugs (57.19 %); and group 4, separately analyzed patients treated with class C and D drugs or only D in combination with class A and B drugs. Thus, 28.11 % of patients at the outpatient stage and 82.75 % of patients at the inpatient stage received drugs with questionable efficacy/safety profiles (class C); 27.17 % of patients at the outpatient stage and 26.52 % at the inpatient stage received potentially inappropriate drugs (class D). At the outpatient stage in groups 2-4, most of patients (51.43–70.59 %) had >5 diseases (pmg=0.020). At the inpatient stage, there were no significant differences between groups in the number of diseases (pmg=0.349). The groups were comparable in the left ventricular ejection fraction depending on the CHF type (pmg=0.027 and pmg=0.778) at both stages of treatment. For instance, the same patient with preserved left ventricular ejection fraction could be included into EURO FORTA group 2 for the analysis of outpatient treatment while after prescription of the inpatient treatment, he/she could be included into group 3; pmg (intergroup, detecting differences for comparison of 3 groups) exceeded 0.017; therefore, the groups were comparable in the number of CHF patients with reduced, mid-range, and preserved left ventricular ejection fraction.Conclusion Every second patient of the study had more than 5 diseases. Every third patient did not take any drugs at the outpatient stage. 28.11 % of patients received EURO FORTA class C drugs and 27.17% of patients received class D drugs at the outpatient stage. The drugs to be avoided in CHF, included primarily nonsteroid anti-inflammatory drugs (NSAIDs) and class I and III anti-arrhythmic medications (except for amiodarone). At the inpatient stage, 82.75 % of patients received EURO FORTA class C drugs and 26.52 % of patients received class D drugs. NSAIDs and ciprofloxacin prevailed among the drugs to be avoided in CHF.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results